Blake Mandell is Co-Founder and CEO of Transcend Therapeutics, where he oversees the day-to-day management and long-term vision of the New York-based biotechnology company. Under Mr. Mandell’s leadership, Transcend has achieved several notable milestones, including raising >$41M in venture capital funds; being awarded a collaborative grant award between Yale University and the U.S. Department of Defense to study Transcend’s lead compound; and positive interim results from an ongoing Phase II clinical trial of TSND-201 for PTSD. Prior to Transcend, Mr. Mandell led the frontier technology practice at the venture capital firm AlleyCorp, where he helped incubate Pearl Health (>$100M raised). Earlier in his career, Mr. Mandell was a consultant at BCG. Mr. Mandell received his bachelor degree in mathematics and contemplative studies from Brown University, and a master’s in economics from Yenching Academy of Peking University in China. He was selected by Forbes as “30 under 30” and has lectured at University of Pennsylvania and Brown University.